A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale
Tofacitinib (pan JAK inhibitor) inhibits T helper 2 (Th2), Th1, Th17, and Th22 cell lines, and thus has potential for refractory AD. There is a need to generate tissue-based cytokine expression data in Indian patients with AD.
Authors
- Ananta Khurana (ORCID: https://orcid.org/0000-0001-7020-7777)
- Savitha Sharath (ORCID: https://orcid.org/0000-0001-7012-8964)
- Bhawuk Dhir (ORCID: https://orcid.org/0000-0002-9105-3372)
- Sumitra Kumari Meena
- Kabir Sardana (ORCID: https://orcid.org/0000-0003-1757-3406)
Institutions
- Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital (IN)
- Institute of Medical Sciences (IN)
Publication Details
- Journal
- Indian Dermatology Online Journal
- Published
- 2025-04-15
- DOI
- https://doi.org/10.4103/idoj.idoj_665_24
- Citations
- 4
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 8.02